185 related articles for article (PubMed ID: 37077658)
1. miR-31-5p as a Potential Circulating Biomarker and Tracer of Clinical Improvement for Chronic Inflammatory Demyelinating Polyneuropathy.
Dziadkowiak E; Baczyńska D; Wieczorek M; Olbromski M; Moreira H; Mrozowska M; Budrewicz S; Dzięgiel P; Barg E; Koszewicz M
Oxid Med Cell Longev; 2023; 2023():2305163. PubMed ID: 37077658
[TBL] [Abstract][Full Text] [Related]
2. Disease activity in chronic inflammatory demyelinating polyneuropathy: association between circulating B-cell subsets, cytokine levels, and clinical outcomes.
Ozdag Acarli AN; Tuzun E; Sanli E; Koral G; Akbayir E; Cakar A; Sirin NG; Soysal A; Aysal F; Durmus H; Parman Y; Yilmaz V
Clin Exp Immunol; 2024 Jan; 215(1):65-78. PubMed ID: 37638717
[TBL] [Abstract][Full Text] [Related]
3. Motor unit number index (MUNIX) in chronic inflammatory demyelinating polyneuropathy: A potential role in monitoring response to intravenous immunoglobulins.
Lawley A; Seri S; Rajabally YA
Clin Neurophysiol; 2019 Oct; 130(10):1743-1749. PubMed ID: 31400577
[TBL] [Abstract][Full Text] [Related]
4. Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy.
Kuitwaard K; van Doorn PA; Bengrine T; van Rijs W; Baas F; Nagelkerke SQ; Kuijpers TW; Fokkink WR; Bunschoten C; Broers MC; Willemsen SP; Jacobs BC; Huizinga R
Eur J Neurol; 2021 May; 28(5):1677-1683. PubMed ID: 33460483
[TBL] [Abstract][Full Text] [Related]
5. Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins.
Ritter C; Bobylev I; Lehmann HC
J Neuroinflammation; 2015 Aug; 12():148. PubMed ID: 26268846
[TBL] [Abstract][Full Text] [Related]
6. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin.
Cirillo G; Todisco V; Tedeschi G
Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579
[TBL] [Abstract][Full Text] [Related]
7. IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Ritter C; Förster D; Albrecht P; Hartung HP; Kieseier BC; Lehmann HC
J Neuroimmunol; 2014 Sep; 274(1-2):225-9. PubMed ID: 25002077
[TBL] [Abstract][Full Text] [Related]
8. Sialylated IgG-Fc: a novel biomarker of chronic inflammatory demyelinating polyneuropathy.
Wong AH; Fukami Y; Sudo M; Kokubun N; Hamada S; Yuki N
J Neurol Neurosurg Psychiatry; 2016 Mar; 87(3):275-9. PubMed ID: 25814494
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulins in patients with clinically suspected chronic immune-mediated neuropathy.
Lucke IM; Adrichem ME; Wieske L; van der Kooi AJ; Verhamme C; van Schaik IN; Eftimov F
J Neurol Sci; 2019 Feb; 397():141-145. PubMed ID: 30623818
[TBL] [Abstract][Full Text] [Related]
10. Circulating miR-155-5p as a Novel Biomarker of Lumbar Degenerative Disc Disease.
Divi SN; Markova DZ; Fang T; Guzek R; Kurd MF; Rihn JA; Hilibrand AS; Anderson DG; Vaccaro AR; Schroeder GD; Kepler CK
Spine (Phila Pa 1976); 2020 May; 45(9):E499-E507. PubMed ID: 31770330
[TBL] [Abstract][Full Text] [Related]
11. Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy.
Rajabally YA; Afzal S
J Neurol; 2019 Feb; 266(2):461-467. PubMed ID: 30556098
[TBL] [Abstract][Full Text] [Related]
12. [Clinical and long-term characteristics of the subtypes of chronic inflammatory demyelinating polyneuropathy].
Shimizu F; Nemoto J; Takeshita Y; Maeda T; Koga M; Kanda T
Rinsho Shinkeigaku; 2022 Mar; 62(3):173-177. PubMed ID: 35228460
[TBL] [Abstract][Full Text] [Related]
13. NK cell markers predict the efficacy of IV immunoglobulins in CIDP.
Mausberg AK; Heininger MK; Meyer Zu Horste G; Cordes S; Fleischer M; Szepanowski F; Kleinschnitz C; Hartung HP; Kieseier BC; Stettner M
Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 33008921
[TBL] [Abstract][Full Text] [Related]
14. IVIG efficacy in CIDP patients is not associated with terminal complement inhibition.
Keller CW; Quast I; Dalakas MC; Lünemann JD
J Neuroimmunol; 2019 May; 330():23-27. PubMed ID: 30772754
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of intravenous immunoglobulin in CIDP.
Vucic S; Black K; Baldassari LE; Tick Chong PS; Dawson KT; Cros D
Clin Neurophysiol; 2007 Sep; 118(9):1980-4. PubMed ID: 17604689
[TBL] [Abstract][Full Text] [Related]
16. A new treatment regimen with high-dose and fractioned immunoglobulin in a special subgroup of severe and dependent CIDP patients.
Debs R; Reach P; Cret C; Demeret S; Saheb S; Maisonobe T; Viala K
Int J Neurosci; 2017 Oct; 127(10):864-872. PubMed ID: 27918219
[TBL] [Abstract][Full Text] [Related]
17. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.
Mielke O; Bril V; Cornblath DR; Lawo JP; van Geloven N; Hartung HP; Lewis RA; Merkies ISJ; Sobue G; Durn B; Shebl A; van Schaik IN;
J Peripher Nerv Syst; 2019 Mar; 24(1):72-79. PubMed ID: 30672067
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and treatment response in the asymmetric variant of chronic inflammatory demyelinating polyneuropathy.
Lucke IM; Wieske L; van der Kooi AJ; van Schaik IN; Eftimov F; Verhamme C
J Peripher Nerv Syst; 2019 Jun; 24(2):174-179. PubMed ID: 31090121
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy.
Dyer WB; Tan JC; Day T; Kiers L; Kiernan MC; Yiannikas C; Reddel S; Ng K; Mondy P; Dennington PM; Dean MM; Trist HM; Dos Remedios C; Hogarth PM; Vucic S; Irving DO
Brain Behav; 2016 Oct; 6(10):e00516. PubMed ID: 27781132
[TBL] [Abstract][Full Text] [Related]
20. Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy.
Seino Y; Nakamura T; Hirohata M; Kawarabayashi T; Okushima T; Shoji M
Intern Med; 2019 Mar; 58(6):855-859. PubMed ID: 30449785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
